Fibrin clot structure in patients with end-stage renal disease

Thrombosis and Haemostasis

Volumn 98, Issue 2, 2007, Pages 339-345

  Sjøland, Jonas A ^a,b   Sidelmann, Johannes J ^a,b   Brabrand, Mikkel ^a   Pedersen, Robert S ^a   Pedersen, Jørgen H ^c   Esbensen, Kim ^c   Standeven, Kristina F ^d   Ariëns, Robert A S ^d   Gram, Jørgen ^a,b  

^a ESBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Azothemia; Fibrinogen; Fibrinolysis; Inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRIN; FIBRINOGEN; INTERLEUKIN 6;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MALE; PERMEABILITY; PLASMA; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TURBIDITY; UREMIA;

AZOTEMIA; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; FIBRIN; FIBRINOLYSIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PERMEABILITY;

EID: 34547907069     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-12-0715     Document Type: Article

References (48)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
2. Yao Q, Pecoits-Filho R, Lindholm B, et al. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405-416.
3. Astrup T. The biological significance of fibrinolysis. Lancet 1956; 271: 565-568.
4. Laurens N, Koolwijk P, de Maat MPM. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-939.
5. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
6. Sidelmann JJ, Gram J, Jespersen J, et al. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000; 26: 605-618.
7. Standeven KF, Ariëns RAS, Grant PJ. The molecular physiology and pathology of fibrin stracture/function. Blood Rev 2005; 19: 275-288.
8. Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem 1979; 254: 11272-11281.
9. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63: 111-128.
10. Ariëns RAS, Lai T-S, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-754.
11. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
12. Greilich PE, Carr ME, Zekert SL, et al. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 1994; 307: 15-20.
13. Mills JD, Ariëns RAS, Mansfield MW, et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
14. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
15. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
16. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
17. Blombäck B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity Biochim Biophys Acta 1989; 997: 96-110.
18. Undas A, Stepien E, Tracz W, et al. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4: 973-975.
19. Fatah K, Hamsten A, Blombäck B, et al. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
20. Undas A, Celinska-Löwenhoff M, Löwenhoff T, et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
21. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337.
22. Yao Q, Axelsson J, Stenvinkel P, et al. Chronic systemic inflammation in dialysis patients: an update on causes and consequences. ASAIO J 2004; 50: lii-lvii.
23. Holloway DS, Vagher JP, Caprini JA, et al. Thrombelastography of blood from subjects with chronic renal failure. Thromb Res 1987; 45: 817-825.
24. Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: a viscoelastic study. J Clin Anesth 1997; 9: 442-445.
25. Clauss A. Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246.
26. Sjøland JA. A new optimized method for the determination of fibrin clot permeability. Blood Coagul Fibrinolysis 2005; 16: 579-583.
27. Nair CH, Azhar A, Dhall DP. Studies on fibrin network structure in human plasma. Part one: methods for clinical application. Thromb Res 1991; 64: 455-476.
28. Carr ME, Jr., Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50.
29. Carr ME, Gabriel DA. Dextran-induced changes in fibrin fiber size and density based on wavelength dependence of gel turbidity. Macromolecules 1980; 13: 1473-1477.
30. Wolberg AS, Gabriel DA, Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 2002; 13: 533-539.
31. Sidelmann J, Jespersen J, Kluft C, et al. The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors. Clin Chim Acta 1997; 261: 43-56.
32. Kluft C. Elimination of inhibition in euglobutin fibrinolysis by use of flufenamate: involvement of C1-in-activator. Haemostasis 1977; 6: 351-369.
33. Cooper AV, Standeven KF, Ariëns RAS. Fibrinogen gamma-chain splice variant γ alters fibrin formation and structure. Blood 2003; 102: 535-540.
34. Andrle R. The angle measure technique: a new method for characterizing the complexity of geomorphic lines. Math Geol 1994; 26: 83-97.
35. Esbensen KH, Hjelmen KH, Kvaal K. The AMT approach in chemometrics - first forays. J Chemometrics 1996; 10: 569-590.
36. Johansen SMB, Laugesen JL, Frøst MB. Image analysis toolbox (MLAT) for Mattab. Available at: http://www.models.kvl.dk/source/TMAT/ index.asp. Accessed December 6, 2006
37. Huang J, Esbensen KH. Applications of angle measure technique (AMT) in image analysis. Part I. A new methodology for in situ powder characterization. Chemometr Intell Lab Syst 2000; 54: 1-19.
38. Van Hylckama Vlieg A, Komanasin N, Ariëns RAS, et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169-175.
39. Carter AM, Catto AJ, Grant PJ. Association of the α-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426.
40. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions Aα312 and Bβ448. Blood 1993; 82: 2117-2124.
41. Thomas AE, Green FR, Kelleher CH, et al. Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991; 65: 487-490.
42. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
43. Blombäck B, Banerjee D, Carlsson K, et al. Native fibrin gel networks and factors influencing their formation in health and disease. Adv Exp Med Biol 1990; 281: 1-23.
44. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
45. Dunn EJ, Ariëns RAS, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood 2004; 103: 1735-1740.
46. Collet J-P, Lesty C, Montalescot G, et al. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 278: 21331-21335.
47. Sjøland JA, Pedersen RS, Jespersen J, et al. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005; 100: c105-c110.
48. Parise P, Morini M, Agnelli G, et al. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis 1993; 4: 721-727.